Hypermethylated RASAL1's Promotive Role in Chemoresistance and Tumorigenesis of Choriocarcinoma Was Regulated by TET2 but Not DNMTs

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2024 Aug 8

PMID 39118077

Authors

Xianling Zeng

Ruifang An

Ruixia Guo

Han Li

Affiliations

Soon will be listed here.

Abstract

Background: Patients with choriocarcinoma (CC) accompanying chemoresistance conventionally present a poor prognosis. Whether ras protein activator like-1 (RASAL1) functions as a tumor promoter or suppressor depends on tumor types. However, the role of RASAL1 in process of chemoresistance of CC and underlying molecular mechanism remain elusive.

Methods: The expression pattern of RASAL1 in CC cells and tissues was measured using Western blotting, immunohistochemistry and qRT-PCR. Cell viability and proliferative ability were assessed by MTT assay, Tunnel assay and flow cytometric analysis. Additionally, the stemness was evaluated by the colony formation and tumor sphere formation. Methotrexate (MTX) was applied to exam the chemosensitivity of CC cells.

Results: The expression of RASAL1 was reduced both at the protein and mRNA levels in CC tissues and cells compared to hydatidiform mole (HM) and invasive mole (IM). Loss of RASAL1 was attributed to its promoter hypermethylation and could be restored by 5-Aza. Knock-down of RASAL1 promoted the viability, proliferative potential, stemness and EMT phenotype of JEG-3 cells. However, induced overexpression of RASAL1 by 5-Aza significantly prohibited cell proliferation and stemness potential of the JAR cell. Additionally, the xenograft model indicated that knockdown of RASAL1 led to a remarkable increase of tumor volume and weight in comparison with its counterpart. Moreover, the stimulatory activity brought by decrease of RASAL1 could be deprived by β-catenin inhibitor XAV 939, yet the suppressive activity resulted from its promoter demethylation could be rescued by β-catenin activator BML-284, indicating that function of RASAL1 depends on β-catenin. Besides, the co-immunoprecipitation assay confirmed the physical binding between RASAL1 and β-catenin. Further investigations showed hypermethylated RASAL1 was regulated by TET2 but not DNMTs.

Conclusion: Taken together, the present data elucidated that reduced RASAL1 through its promoter hypermethylation regulated by TET2 promoted the tumorigenicity and chemoresistance of CC via modulating β-catenin both in vitro and in vivo.

References

Ju F, Atyah M, Horstmann N, Gul S, Vago R, Bruns C . Characteristics of the cancer stem cell niche and therapeutic strategies. Stem Cell Res Ther. 2022; 13(1):233. PMC: 9166529. DOI: 10.1186/s13287-022-02904-1. View

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

Winter M . Treatment of low-risk gestational trophoblastic neoplasia. Best Pract Res Clin Obstet Gynaecol. 2021; 74:67-80. DOI: 10.1016/j.bpobgyn.2021.01.006. View

Clark J, Slater S, Seckl M . Treatment of gestational trophoblastic disease in the 2020s. Curr Opin Obstet Gynecol. 2020; 33(1):7-12. PMC: 7116872. DOI: 10.1097/GCO.0000000000000674. View

Lurain J . Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol. 2010; 204(1):11-8. DOI: 10.1016/j.ajog.2010.06.072. View

Dongre A, Weinberg R . New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2018; 20(2):69-84. DOI: 10.1038/s41580-018-0080-4. View

Qiao F, Su X, Qiu X, Qian D, Peng X, Chen H . Enforced expression of RASAL1 suppresses cell proliferation and the transformation ability of gastric cancer cells. Oncol Rep. 2012; 28(4):1475-81. DOI: 10.3892/or.2012.1920. View

Berkowitz R, Goldstein D . Current management of gestational trophoblastic diseases. Gynecol Oncol. 2008; 112(3):654-62. DOI: 10.1016/j.ygyno.2008.09.005. View

Singh A, Settleman J . EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29(34):4741-51. PMC: 3176718. DOI: 10.1038/onc.2010.215. View

10.

Abu-Rustum N, Yashar C, Bean S, Bradley K, Campos S, Chon H . Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17(11):1374-1391. DOI: 10.6004/jnccn.2019.0053. View

11.

Calvisi D, Ladu S, Conner E, Seo D, Hsieh J, Factor V . Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol. 2010; 54(2):311-9. PMC: 3031080. DOI: 10.1016/j.jhep.2010.06.036. View

12.

Kaur B . Pathology of gestational trophoblastic disease (GTD). Best Pract Res Clin Obstet Gynaecol. 2021; 74:3-28. DOI: 10.1016/j.bpobgyn.2021.02.005. View

13.

Vessoni A, Filippi-Chiela E, Lenz G, Batista L . Tumor propagating cells: drivers of tumor plasticity, heterogeneity, and recurrence. Oncogene. 2019; 39(10):2055-2068. DOI: 10.1038/s41388-019-1128-4. View

14.

Ngan H, Seckl M, Berkowitz R, Xiang Y, Golfier F, Sekharan P . Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet. 2021; 155 Suppl 1:86-93. PMC: 9298230. DOI: 10.1002/ijgo.13877. View

15.

Caglar H, Biray Avci C . Alterations of cell cycle genes in cancer: unmasking the role of cancer stem cells. Mol Biol Rep. 2020; 47(4):3065-3076. DOI: 10.1007/s11033-020-05341-6. View

16.

Feinberg A, Koldobskiy M, Gondor A . Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet. 2016; 17(5):284-99. PMC: 4888057. DOI: 10.1038/nrg.2016.13. View

17.

Shibue T, Weinberg R . EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017; 14(10):611-629. PMC: 5720366. DOI: 10.1038/nrclinonc.2017.44. View

18.

Li H, Feng Z, He M . Lipid metabolism alteration contributes to and maintains the properties of cancer stem cells. Theranostics. 2020; 10(16):7053-7069. PMC: 7330842. DOI: 10.7150/thno.41388. View

19.

Lu W, Kang Y . Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis. Dev Cell. 2019; 49(3):361-374. PMC: 6506183. DOI: 10.1016/j.devcel.2019.04.010. View

20.

Zheng X, Carstens J, Kim J, Scheible M, Kaye J, Sugimoto H . Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015; 527(7579):525-530. PMC: 4849281. DOI: 10.1038/nature16064. View